I had a great time at the Stanford Drug Discovery Symposium last month. Two packed days at Li Ka Shing with researchers, pharma leaders, investors, and regulators—plus a healthy dose of AI talk.
What stood out to me: the industry knows it’s time to rethink how we discover drugs. From ARPA-H to Pfizer, everyone’s saying the same thing—AI isn’t a side project anymore. It’s the future of drug development.
At Bioptic, that’s exactly what we’re building for: giving every scientist access to Google-scale AI tools. This symposium confirmed we’re on the right track—and that the time to move is now.
– Andrey Doronichev
